Healthcare
Live Price
Offline$2.20
-0.90% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Aerpio Pharmaceuticals, Inc. (ARPO) is a Healthcare stock with a market cap of $53.67M. The stock last traded around $2.20. Baseline metrics include revenue growth of -72.5%, EPS growth of +86.0%, a dividend yield of 0.0%. What stands out right now is revenue -72.5%, EPS +86.0%, free cash flow -60.1% with operating margin -1601.1% and ROIC -83.9%. Valuation sits in the middle of the pack at price/sales 7.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ARPO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ARPO
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ARPO Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ARPO and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$823.0K
-81.6% YoY
FY Net Income
-$22.2M
+4.2% YoY
Free Cash Flow
-$19.1M
+23.3% YoY
Revenue Growth
-72.5%
EPS Growth
+86.0%
Gross Margin
0.0%
Net Margin
-288.3%
Income statement
USD
| Metric | 2025 | 2024 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 7M | 26M | 6M | 4M | 823K |
| Gross Profit | 0 | 0 | -30M | -16M | -14M |
| Operating Income | -114M | -67M | -37M | -24M | -22M |
| EBITDA | -114M | -67M | -36M | -23M | -20M |
| Net Income | -21M | -64M | -37M | -23M | -22M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 38M | 29M | 15M | 10M | 10M |
| Total Assets | 151M | 70M | 96M | 70M | 40M |
| Total Liabilities | 15M | 18M | 60M | 44M | 21M |
| Shareholder Equity | 136M | 52M | 36M | 25M | 19M |
| Total Debt | 0 | 833K | 0 | 0 | 0 |
| Net Debt | -38M | -28M | -15M | -10M | -10M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
18M
+22.5% YoY
Capital Expenditures
824K
+36.8% YoY
Free Cash Flow
19M
+23.3% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
-1601.1%
Net Margin
-288.3%
ROE
-12.0%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.